Current treatment for chronic hepatitis B in Japan

Clinical Journal of Gastroenterology

Volumn 2, Issue 5, 2009, Pages 325-330

  Ohishi, Waka ^a,b   Chayama, Kazuaki ^b  

^a RADIATION EFFECTS RESEARCH FOUNDATION   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Hepatitis B virus; Interferon; Lamivudine resistant virus; Nucleoside analogue

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ENTECAVIR; HEPATITIS B(E) ANTIGEN; INTERFERON; LAMIVUDINE; NUCLEOSIDE ANALOG; PEGINTERFERON ALPHA; VIRUS DNA;

AGE DISTRIBUTION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIGEN DETECTION; ANTIVIRAL THERAPY; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GLOMERULUS FILTRATION RATE; HEALTH INSURANCE; HEPATITIS B; HUMAN; JAPAN; LIVER CIRRHOSIS; MONOTHERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TREATMENT DURATION; TREATMENT INDICATION;

EID: 70350764018     PISSN: 18657257     EISSN: 18657265     Source Type: Journal    
DOI: 10.1007/s12328-009-0100-1     Document Type: Review

References (37)

1. WM Lee 1997 Hepatitis B virus infection N Engl J Med 337 1733 1745 10.1056/NEJM199712113372406 1:STN:280:DyaK1c%2FktFyjtA%3D%3D 9392700
2. Kumada H (Principal investigator). Research on standardization of treatment for viral liver diseases including liver cirrhosis. FY2008 MHLW-supported found report; 2009.
3. AS Lok BJ McMahon 2007 Chronic hepatitis B Hepatology 45 507 539 10.1002/hep.21513 1:CAS:528:DC%2BD2sXisVKns7o%3D 17256718
4. G Fattovich 2003 Natural history of hepatitis B J Hepatol 39 Suppl 1 S50 S58 10.1016/S0168-8278(03)00139-9 14708678
5. YF Liaw NW Leung TT Chang R Guan DI Tai KY Ng, et al. 2000 Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group Gastroenterology 119 172 180 10.1053/gast.2000.8559 1:CAS:528:DC%2BD3cXlsFGltLs%3D 10889166
6. AS Lok CL Lai N Leung GB Yao ZY Cui ER Schiff, et al. 2003 Long-term safety of lamivudine treatment in patients with chronic hepatitis B Gastroenterology 125 1714 1722 10.1053/j.gastro.2003.09.033 1:CAS:528: DC%2BD2cXhtVOrug%3D%3D 14724824
7. SJ Hadziyannis NC Tassopoulos EJ Heathcote TT Chang G Kitis M Rizzetto, et al. 2005 Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B N Engl J Med 352 2673 2681 10.1056/NEJMoa042957 1:CAS:528:DC%2BD2MXls1Sksbc%3D 15987916
8. MG Brook P Karayiannis HC Thomas 1989 Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors Hepatology 10 761 763 10.1002/hep.1840100502 1:STN:280:DyaK3c%2FjsVKktA%3D%3D 2680866
9. RP Perrillo ER Schiff GL Davis HC Bodenheimer Jr K Lindsay J Payne, et al. 1990 A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group N Engl J Med 323 295 301 1:STN:280: DyaK3czgvF2huw%3D%3D 2195346
10. AS Lok PC Wu CL Lai JY Lau EK Leung LS Wong, et al. 1992 A controlled trial of interferon with or without prednisone priming for chronic hepatitis B Gastroenterology 102 2091 2097 1:STN:280:DyaK383msleitg%3D%3D 1587429
11. F Suzuki Y Arase N Akuta A Tsubota Y Suzuki H Sezaki, et al. 2004 Efficacy of 6-month interferon therapy in chronic hepatitis B virus infection in Japan J Gastroenterol 39 969 974 10.1007/s00535-004-1430-x 1:CAS:528: DC%2BD2cXpt1ehsr4%3D 15549450
12. P Marcellin GK Lau F Bonino P Farci S Hadziyannis R Jin, et al. 2004 Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B N Engl J Med 351 1206 1217 10.1056/NEJMoa040431 1:CAS:528:DC%2BD2cXns12rsr0%3D 15371578
13. AS Lok BJ McMahon 2001 Chronic hepatitis B Hepatology 34 1225 1241 10.1053/jhep.2001.29401 1:STN:280:DC%2BD3MnosV2qtw%3D%3D 11732013
14. DK Wong AM Cheung K O'Rourke CD Naylor AS Detsky J Heathcote 1993 Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis Ann Intern Med 119 312 323 1:STN:280:DyaK3szhvFWqsQ%3D%3D 8328741
15. K Chayama Y Suzuki M Kobayashi M Kobayashi A Tsubota M Hashimoto, et al. 1998 Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy Hepatology 27 1711 1716 10.1002/hep.510270634 1:CAS:528: DyaK1cXjvVCrs78%3D 9620347
16. YF Liaw NW Leung TT Chang R Guan DI Tai KY Ng, et al. 2000 Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group Gastroenterology 119 172 180 10.1053/gast.2000.8559 1:CAS:528:DC%2BD3cXlsFGltLs%3D 10889166
17. R Perrillo HW Hann D Mutimer B Willems N Leung WM Lee, et al. 2004 Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus Gastroenterology 126 81 90 10.1053/j.gastro.2003.10.050 1:CAS:528:DC%2BD2cXhtFGntL0%3D 14699490
18. I Rapti E Dimou P Mitsoula SJ Hadziyannis 2007 Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B Hepatology 45 307 313 10.1002/hep.21534 1:CAS:528: DC%2BD2sXisVKgu70%3D 17256746
19. M Sherman C Yurdaydin J Sollano M Silva YF Liaw J Cianciara, et al. 2006 Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B Gastroenterology 130 2039 2049 10.1053/j.gastro.2006.04.007 1:CAS:528:DC%2BD28XntVWitrw%3D 16762627
20. JH Hoofnagle E Doo TJ Liang R Fleischer AS Lok 2007 Management of hepatitis B: summary of a clinical research workshop Hepatology 45 1056 1075 10.1002/hep.21627 1:CAS:528:DC%2BD2sXltlWitb0%3D 17393513
21. Ha NB, Ha NB, Garcia RT, Trinh HN, Vu AA, Nguyen HA, et al. Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil. Hepatology. 2009; Epub ahead of print.
22. N Leung CY Peng HW Hann J Sollano J Lao-Tan CW Hsu, et al. 2009 Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir Hepatology 49 72 79 10.1002/hep.22658 1:CAS:528:DC%2BD1MXhsFGlt7g%3D 19065670
23. EB Keeffe P Marcellin 2007 New and emerging treatment of chronic hepatitis B Clin Gastroenterol Hepatol 5 285 294 10.1016/j.cgh.2006.09.036 1:CAS:528:DC%2BD2sXkslSlsbk%3D 17218162
24. S Locarnini WS Mason 2006 Cellular and virological mechanisms of HBV drug resistance J Hepatol 44 422 431 10.1016/j.jhep.2005.11.036 1:CAS:528: DC%2BD28XksVSjuw%3D%3D 16364492
25. DJ Tenney RE Rose CJ Baldick KA Pokornowski BJ Eggers J Fang, et al. 2009 Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy Hepatology 49 1503 1514 10.1002/hep.22841 1:CAS:528:DC%2BD1MXlslKmurw%3D 19280622
26. MA McMahon BL Jilek TP Brennan L Shen Y Zhou M Wind-Rotolo, et al. 2007 The HBV drug entecavir-effects on HIV-1 replication and resistance N Engl J Med 356 2614 2621 10.1056/NEJMoa067710 1:CAS:528:DC%2BD2sXmslKjs7o%3D 17582071
27. J Sasadeusz J Audsley A Mijch R Baden J Caro H Hunter, et al. 2008 The anti-HIV activity of entecavir: a multicentre evaluation of lamivudine- experienced and lamivudine-naive patients AIDS 11 22 947 955 10.1097/QAD.0b013e3282ffde91
28. EB Keeffe DT Dieterich SH Han IM Jacobson P Martin ER Schiff, et al. 2008 A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update Clin Gastroenterol Hepatol 6 1315 1341 10.1016/j.cgh.2008.08.021 1:CAS:528:DC%2BD1MXhtFSlurk%3D 18845489
29. SK Sarin M Kumar R Kumar SN Kazim RC Guptan P Sakhuja, et al. 2005 Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients Am J Gastroenterol 100 2463 2471 10.1111/j.1572-0241.2005.00247.x 1:CAS:528:DC%2BD2MXht1OgsrfF 16279901
30. M Minami T Okanoue 2007 Management of HBV infection in Japan Hepatol Res 37 S79 S82 10.1111/j.1872-034X.2007.00109.x 1:CAS:528:DC%2BD1cXkt1OjtLg%3D 17627640
31. W Ohishi H Shirakawa Y Kawakami S Kimura M Kamiyasu S Tazuma, et al. 2004 Identification of rare polymerase variants of hepatitis B virus using a two-stage PCR with peptide nucleic acid clamping J Med Virol 72 558 565 10.1002/jmv.20026 1:CAS:528:DC%2BD2cXislyktrs%3D 14981758
32. C Niederau T Heintges S Lange G Goldmann CM Niederau L Mohr, et al. 1996 Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B N Engl J Med 334 1422 1427 10.1056/NEJM199605303342202 1:STN:280:DyaK283hvVyhtw%3D%3D 8618580
33. CJ Chen HI Yang J Su CL Jen SL You SN Lu, et al. 2006 Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level JAMA 295 65 73 10.1001/jama.295.1.65 1:CAS:528:DC%2BD28XhtlKqtQ%3D%3D 16391218
34. UH Iloeje HI Yang J Su CL Jen SL You CJ Chen, et al. 2006 Predicting cirrhosis risk based on the level of circulating hepatitis B viral load Gastroenterology 130 678 686 10.1053/j.gastro.2005.11.016 16530509
35. PS Tsang H Trinh RT Garcia JT Phan NB Ha H Nguyen, et al. 2008 Significant prevalence of histologic disease in patients with chronic hepatitis B and mildly elevated serum alanine aminotransferase levels Clin Gastroenterol Hepatol 6 569 574 10.1016/j.cgh.2008.02.037 18455697
36. MF Sorrell EA Belongia J Costa IF Gareen JL Grem JM Inadomi, et al. 2009 National Institutes of Health Consensus Development Conference Statement: management of hepatitis B Ann Intern Med 150 104 110 19124811
37. AS Lok RH Liang EK Chiu KL Wong TK Chan D Todd 1991 Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study Gastroenterology 100 182 188 1:STN:280: DyaK3M%2FmtVSiuw%3D%3D 1983820